MOONLAKE IMMUNOTHERAPEUTICS(NASDAQ:MLTX) stock News

MLTX Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: MRK

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery

a month ago - By: Benzinga - Mentions: HOOD GDEV GRDN BKR ...

Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta

2 months ago - By: Zacks Investment Research - Mentions: SNY BMY MRK

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

2 months ago - By: Investor's Business Daily - Mentions: RY RY.CA MRK

MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover

2 months ago - By: Yahoo Finance

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

2 months ago - By: Yahoo Finance - Mentions: MSFT HD SAP INFA ...

Jefferies Names Microsoft (MSFT) Its Top AI Pick After “Build 2025”

2 months ago - By: Yahoo Finance - Mentions: ORKA LUV

Fertility financing 101: How to afford IVF

2 months ago - By: Yahoo Finance - Mentions: ORKA PTON AAPL

H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT

2 months ago - By: Yahoo Finance - Mentions: ORKA RXRX AAPL

H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial

2 months ago - By: Yahoo Finance - Mentions: HD MSFT CMG WMT ...

No Quick Fix for Home Depot (HD) as Market Conditions Deteriorate

2 months ago - By: Zacks Investment Research

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

2 months ago - By: MoonLake Immunotherapeutics AG

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

3 months ago - By: MoonLake Immunotherapeutics AG

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

3 months ago - By: Yahoo Finance - Mentions: AAPL DHI CMG

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

4 months ago - By: MoonLake Immunotherapeutics AG

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

5 months ago - By: MoonLake Immunotherapeutics AG

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

6 months ago - By: MoonLake Immunotherapeutics AG

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

6 months ago - By: MoonLake Immunotherapeutics AG

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

10 months ago - By: MoonLake Immunotherapeutics AG

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

a year ago - By: MoonLake Immunotherapeutics AG

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

a year ago - By: MoonLake Immunotherapeutics AG

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock News

MLTX Latest News, Press Relases and Analysis

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery

Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

Jefferies Names Microsoft (MSFT) Its Top AI Pick After “Build 2025”

Fertility financing 101: How to afford IVF

H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT

H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial

No Quick Fix for Home Depot (HD) as Market Conditions Deteriorate

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa